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Abstract
Background: Clostridioides difficile infection (CDI) has a high recurrent infection rate. Faecal microbiota transplantation
(FMT) has been used successfully to treat recurrent CDI, but much remains unknown about the human gut microbiota
response to replacement therapies. In this study, antibiotic-mediated dysbiosis of gut microbiota and bacterial growth
dynamics were investigated by two quantitative methods: real-time quantitative PCR (qPCR) and direct culture
enumeration, in triple-stage chemostat models of the human colon. Three in vitro models were exposed to clindamycin
to induce simulated CDI. All models were treated with vancomycin, and two received an FMT. Populations of total
bacteria, Bacteroides spp., Lactobacillus spp., Enterococcus spp., Bifidobacterium spp., C. difficile, and Enterobacteriaceae were
monitored using both methods. Total clostridia were monitored by selective culture. Using qPCR analysis, we additionally
monitored populations of Prevotella spp., Clostridium coccoides group, and Clostridium leptum group.
Results: Both methods showed an exacerbation of disruption of the colonic microbiota following vancomycin (and
earlier clindamycin) exposure, and a quicker recovery (within 4 days) of the bacterial populations in the models that
received the FMT. C. difficile proliferation, consistent with CDI, was also observed by both qPCR and culture. Pearson
correlation coefficient showed an association between results varying from 98% for Bacteroides spp., to 62% for
Enterobacteriaceae.
Conclusions: Generally, a good correlation was observed between qPCR and bacterial culture. Overall, the molecular
assays offer results in real-time, important for treatment efficacy, and allow the monitoring of additional microbiota
groups. However, individual quantification of some genera (e.g. clostridia) might not be possible without selective culture.
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Background
Clostridioides difficile infection (CDI) is a healthcare-
associated infection related with high morbidity, mortal-
ity and costs [1]. Vancomycin and fidaxomicin are the
recommended antibiotics for the treatment of moderate
to severe CDI, but recurrent infection rates can be as
high as 20–30% [1–4]. Faecal microbiota transplantation
(FMT) has been used successfully as treatment for recurrent
CDI (rCDI), with reported resolution rates that can reach ~
90% [5–7]. However, much remains unknown about the hu-
man gut microbiota composition and behaviour, particularly
in undefined microbiota replacement therapy, such as FMT.
The chemostat model has been validated against the
intestinal contents of sudden-death victims and consists
on a reliable representation on the microbial content
and bacterial activities of the human colon [8]. This
model of the human colon has been used to investigate
the propensity of different antibiotics to induce CDI and
the efficacy of treatments [9–15]. The results observed
in the gut model have shown to correlate well with
phase three clinical trials [9, 14], underlining the clinical
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relevance of this system. Bacteroides spp., Bifidobacter-
ium spp. and Clostridium spp., are examples of bacterial
genera highly abundant in the human gut that are often
disrupted by antimicrobial therapy, as shown by ex vivo
and in vitro studies [5, 12–14, 16–20]. The decline of
microbial populations creates a potential niche for C.
difficile spore germination, cell proliferation and toxin
production, leading to CDI [9]. In the previous gut
model studies, variations in microbial populations were
investigated using bacterial culture. The accuracy of the
gut model studies predicting clinical outcomes suggests
that the bacterial populations targeted provide a suitable
representation of the healthy human microbiota [17].
However, some important groups of the human gut
microbiota are difficult to monitor by this method due
to taxonomic complexity. Furthermore, bacterial culture
is demanding on staff time and requires between 24 h
and 48 h of plate incubation for colony growth, which
can delay interventions to the model; e.g. commencement
of antibiotic course during simulated CDI. Similar to bac-
terial culture, real-time PCR methodology can be used to
investigate gut microbiota variations from a quantitate per-
spective [19–23], but populations targeted by this method
may differ from those investigated by direct culture. Taxo-
nomic profiling using 16S sequencing can also be used to
increase our understanding of the gut microbiota popula-
tions exposed to antibiotic pressure [5, 18, 24]. However,
the variations observed by 16S sequencing are qualitative,
as bacterial groups differ in the number of 16S gene copies
encoded on their genomes. Additionally, gut microbiota ex-
posure to antibiotics can create ‘artefacts’, as the proportion
of reads assigned to a bacterial population may increase as
result of the depletion of abundant bacterial populations,
and not due to bacterial expansion.
To better understand the dynamics of bacterial popula-
tions during replacement therapy and infection, we investi-
gated the gut microbiota reconstitution following a
simulated FMT, alongside an experiment of rCDI, using
in vitro chemostat models of the human colon. Direct
enumeration of key bacterial groups was monitored using
two quantitative methodologies: selective bacteriological
agars, and real-time quantitative PCR (qPCR). The advan-
tages and disadvantages of each methodology, when applied
to studies of the human gut microbiota, is investigated.
Results
Bacterial populations monitored by qPCR and bacterial
culture
Gut microbiota variations were monitored in three chemo-
stat models of the human colon, here described as A, B and
C. Project outline is shown in Fig. 1. All models were
started with the same human faecal slurry and underwent
clindamycin induced CDI, followed by treatment with
vancomycin. Up to the end of vancomycin treatment all
models experienced the same experimental design, repre-
senting technical replicates. Bacterial populations were
monitored in vessel 3 of model A, B and C throughout the
experiment, using bacterial culture and qPCR assays. As
the bacterial populations showed minor variations, only the
mean logarithm values of the three models is shown. Fol-
lowing vancomycin instillation, model A was left without
additional treatment, representing simulated rCDI. Three
days post completion of vancomycin treatment, models B
and C received FMT therapy. This three-day period allowed
the washout of vancomycin to prevent residual antibiotic
effects on the transplanted microbiota. The post-FMT re-
sults are shown as the mean of model B and C data, or
model A only.
Real-time PCR assays species- and group-specific were
applied to DNA extracted from gut model samples at key
stages of the experiment to monitor population dynamics.
Furthermore, total bacteria, Bacteroides spp., Lactobacillus
spp., Enterococcus spp., Bifidobacterium spp., and C. diffi-
cile were also monitored using culture assay.
qPCR and bacterial culture analyses showed that the total
bacterial populations remained stable throughout the experi-
ment except for a decline of ~ 1 log10 copies/μL and ~ 1
log10 cfu/mL, respectively, observed following clindamycin
Fig. 1 Experimental timeline for the recurrent CDI model A, and the faecal microbiota transplantation (FMT) models B and C. All models followed
the same experimental design to induce and treat simulated CDI with clindamycin and vancomycin, respectively. Following treatment course
with vancomycin, model A received no further intervention (red arrow), whereas model B and C received an FMT three days post vancomycin
treatment (purple arrow). Black lines indicate the times at which samples were collected for qPCR and culture analysis
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dosing. The qPCR data showed this decline to be significant
(p < 0.005) (Fig. 2a). qPCR data also showed a significant
(p < 0.005) increase in total bacteria following gut microbiota
reconstitution by FMT in models B and C. For the Bacter-
oides spp. population (Fig. 2b), clindamycin instillation
caused a significant decline of ~ 1 log10 copies/μL (p <
0.0005), followed by recovery (p < 0.005) during CDI phase.
Vancomycin dosing led to a ~ 4 log10 copies/μL decline (p <
0.005). In model A, Bacteroides spp. recovered only by the
end of the experiment, whereas in model B and C an in-
crease of ~ 3.5 log10 copies/μL (p < 0.0005) was observed
four days after FMT. Bacterial culture results showed similar
variations in Bacteroides spp., namely a ~ 2 log10 cfu/mL de-
cline was observed following clindamycin dosing and ~ 7
log10 cfu/mL decline was observed following vancomycin in-
stillation, with a faster recovery to steady state levels being
observed in model B and C. Analysis by qPCR showed sig-
nificant declines in Lactobacillus spp. (p < 0.005) (Fig. 2c),
and Enterococcus spp. (p < 0.0005) (Fig. 2d) populations dur-
ing CDI period, followed by a further decline caused by
vancomycin instillation (p < 0.0005). Culture populations of
Lactobacillus spp. and Enterococcus spp. remained stable up
to vancomycin dosing that caused a ~ 1.0 log10 cfu/mL de-
cline in both populations. In model B and C, both qPCR
and culture data showed a recovery of Enterococcus spp.
populations to steady state levels following FMT.
Bifidobacterium spp. populations analysed by qPCR were
stable prior to clindamycin instillation, which caused a ~ 1
Fig. 2 Mean gut microbiota populations of (a) total bacteria, (b) Bacteroides spp., (c) Lactobacillus spp., (d) Enterococcus spp., and (e) C. difficile in
vessel 3 of model A, B and C at the different stages of the experiment. Bars represent the levels in log10 copies/μL measured by qPCR, and lines
represent the populations levels in log10 cfu/mL measured by bacterial culture. CD, C. difficile; rCDI, recurrent CDI; FMT, faecal microbiota
transplantation. Asterisks represent significant variations by qPCR between time points: *correspond to p < 0.05, **correspond to p < 0.005, and
***correspond to p < 0.0005
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log10 copies/μL (p < 0.005) decline to ~ 7 log10 copies/μL,
followed by recovery to steady state levels during CDI (p <
0.005). Vancomycin instillation also caused a decline of ~
1.5 log10 copies/μL (p < 0.0005). No significant variations
were observed in model B and C following FMT. In all
models, Bifidobacterium spp. populations recovered by the
end of the experiment. Culture-based analysis showed a de-
pletion of Bifidobacterium spp. during clindamycin (~ 6
log10 cfu/mL) and vancomycin to below the culture assay
limit of detection. In model A, Bifidobacterium spp.
remained undetected by culture until the end of the experi-
ment. Following FMT, Bifidobacterium spp. increased ~ 2.5
log10 cfu/mL in model B and C and recovered to steady
state levels (~ 8 log10 cfu/mL) by the end of the experiment.
C. difficile was investigated using qPCR assays for the
16S gene and the housekeeping gene gluD (Fig. 2e and
Additional file 1: Figure S1). In both assays, C. difficile
copy number declined ~ 1.5 log10 copies/μL (p < 0.0005)
during clindamycin instillation. This was followed by ~
2.2 log10 copies/μL increase (p < 0.0005) post antibiotic
period, consistent with C. difficile cell proliferation in
the gut models, and was accompanied by toxin produc-
tion, corresponding to simulated CDI. Average toxin
value prior to vancomycin treatment was 2 relative units
(RUs). Vancomycin treatment caused a decline in C. dif-
ficile populations of ~ 3 log10 copies/μL (p < 0.0005) and
toxin declined to undetectable levels. In model A, a ~
1.4 log10 copies/μL increase in C. difficile was observed
towards the end of the experiment (p < 0.05). This was
accompanied by toxin production corresponding to 3
RUs, which is consistent with rCDI. Following the FMT
in models B and C, no significant increase in C. difficile
copy number was observed and no toxin was detected,
suggesting resolution of CDI (Fig. 2e). Monitoring of C.
difficile by culture showed a ~ 2 log10 cfu/mL decline in
C. difficile counts following clindamycin dosing. C. diffi-
cile population then increased ~ 3 log10 cfu/mL consist-
ent with cell proliferation. C. difficile declined to below
the limit of detection with vancomycin instillation and
remained low up to the end of the experiment when a
sudden increase consistent with spore germination and
cell proliferation, was observed in model A only.
Gut microbiota populations monitored by qPCR
Prevotella spp. and C. leptum are important bacterial
populations in the human microbiome [19], however;
these groups could only be monitored by qPCR due to
lack of selective agars available (Fig. 3). Prevotella spp.
and C. leptum did not significantly change following the
addition of C. difficile spores. Clindamycin caused a ~ 1
log10 copies/μL (p < 0.0005) decline in Prevotella spp.,
followed by recovery during CDI phase (p < 0.005)
(Fig. 3a). Vancomycin treatment also caused a decline of
~ 4 log10 copies/μL (p < 0.0005). In model A, Prevotella
spp. recovered by the end of the experiment. In models
B and C, the FMT led to a ~ 4 log10 copies/μL (p <
0.0005) recovery within 4 days. Although a decline in C.
leptum was observed during clindamycin instillation, this
was not significant (Fig. 3b). Vancomycin dosing caused
a decline of ~ 3 log10 copies/μL (p < 0.0005). Full recov-
ery of this population was observed at the end of the ex-
periment for all models, but in model B and C,
population level increased earlier, showing a ~ 1 log10
copies/μL (p < 0.0005) recovery just 4 days post-FMT.
Individually monitoring of selected populations
In this study, the qPCR results for C. coccoides were cor-
related with the culture data for Clostridium spp..
Among the primer pairs used in this study, the C. coc-
coides primers showed the higher specificity for the
Fig. 3 Gut microbiota populations of a) Prevotella spp., and (b) C. leptum in vessel 3 of model A, B and C, investigated by qPCR only. CD, C.
difficile; rCDI, recurrent CDI; FMT, faecal microbiota transplantation. Asterisks represent significant variations between time points: *correspond to
p < 0.05, **correspond to p < 0.005, and ***correspond to p < 0.0005
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Clostridium species most commonly isolated from the
gut model, being able to amplify 9 out of the 13 species
investigated (Table 1). In addition to Clostridium species
[17, 24], C. coccoides group includes species from several
other genus. Due to its complexity, the populations that
constitute the C. coccoides group were monitored by
qPCR (Fig. 4a). Declines in C. coccoides, of ~ 1 log10 cop-
ies/μL (p < 0.005) and ~ 2 log10 copies/μL (p < 0.0005),
were observed as a result of clindamycin and vanco-
mycin dosing, respectively. In model B and C, this popula-
tion recovered ~ 1.5 log10 copies/μL (p < 0.0005) post-
FMT. Selective culture allowed the monitoring of several
commensal clostridia species of the human microbiota
(Fig. 4b). In this study, selective culture showed declines
in total clostridia counts following clindamycin (~ 2 log10
cfu/mL) and vancomycin (~ 5 log10 cfu/mL). In model A,
clostridia populations recovered within 4 weeks, whereas
in model B and C a ~ 2 log10 cfu/mL increase was ob-
served 4 days post-FMT. Clindamycin instillation caused
an increase in both Enterobacteriaceae populations moni-
tored by qPCR (~ 1 log10 copies/μL, p < 0.0005) (Fig. 4c)
and lactose-fermenting Enterobacteriaceae monitored by
selective culture (~ 1 log10 cfu/mL) (Fig. 4d). qPCR ana-
lysis showed a decline of ~ 1 log10 copies/μL in Enterobac-
teriaceae following vancomycin instillation (p < 0.0005);
however, data of direct culture showed that lactose-
fermenting Enterobacteriaceae populations increased ~ 1
log10 cfu/mL during this stage. According to qPCR, the
FMT did not significantly affect Enterobacteriaceae popu-
lations. However, culture data showed a decline of ~ 1
log10 cfu/mL in lactose-fermenting populations in model
B and C, 4 days post-treatment.
Correlation between bacterial culture and qPCR assays
A Pearson correlation coefficient was used to determine
the relationship between bacterial populations enumer-
ated by qPCR measurements and culture-based methods
(Table 2). The higher correlation between methods was
observed for bacterial genus/species targeted by both
methods. This was particularly seen in Bacteroides spp.,
as the bacterial levels detected throughout the study
showed a correlation of 98% between methods, suggest-
ing these assays target the same Bacteroides populations
within the gut models. Good correlations were also ob-
served for Lactobacillus spp., Enterococcus spp. and Bifi-
dobacterium spp., corresponding to 94, 85 and 73%,
respectively. The linear relationship between methods
for all these populations was > 0.85. As the models are
maintained in anaerobic conditions, for the correlation
analysis, the qPCR data targeting total Eubacteria was
compared the counts of total bacteria cultured in anaer-
obic conditions, with an association of 86% between as-
says. Unsurprisingly, given the slightly different targets
of qPCR and culture enumeration, the lower correlation
values were observed for Enterobacteriaceae (62%) and
clostridia (63%), with both assays showing a linear rela-
tionship of 0.79. These correlation values were highly af-
fected by the results observed in each assay during
antibiotic instillation. The correlation analysis for En-
terobacteriaceae showed the most variation during
vancomycin dosing. Similarly, Clostridium spp. direct
enumeration and C. coccoides qPCR assay showed the
most variation during clindamycin dosing, which de-
clined the linear correlation between assays from 0.91 to
the reported 0.79.
Table 1 Amplification of Clostridium species commonly isolated in gut model samples using the Clostridium specific primers
Strain Primers
Sg-clept-F and Sg-clept-R Eub338F and Erec482R Cdiff-F and Cdiff-R
Clostridium difficile – + +
Clostridium hathewayi – + –
Clostridium celerecrescens/ Clostridium sphenoidesa – + –
Clostridium sporogenes – – –
Clostridium paraputrificum – + –
Clostridium tertium – + –
Clostridium butyricum – – –
Clostridium clostridioforme – + –
Clostridium symbiosum – + –
Clostridium bolteae – + –
Clostridium innocuum – – –
Clostridium scindens – + –
Escherichia colib – – –
aStrains sharing 98% of 16S rRNA gene homology [25], Maldi-ToF identification did not provide reliable distinction between species
bIncluded in each assay as negative control
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Discussion
Gut microbiota variations and microbiota reconstitution
were monitored in three chemostat in vitro models of the
human colon using two methods of quantitative bacterial
enumeration: culture-based assay and qPCR. Models A, B
and C underwent clindamycin induced CDI followed by
treatment with vancomycin. In model A, CDI was treated
with vancomycin only, whereas in models B and C vanco-
mycin treatment was followed by an FMT. Post-treatment,
bacterial populations were allowed four weeks to recover.
Similar to previous in vitroEscherichia coli cells gut model
studies [10–13] antibiotic therapy with clindamycin and
vancomycin caused a decline in several of the bacterial popu-
lations monitored, particularly Bifidobacterium spp., Bacter-
oides spp., clostridia, Enterococcus spp., Lactobacillus spp.,
and C. difficile. Disruption of the gut microbiota was exacer-
bated following vancomycin dosing, with these declines being
observed by both bacterial culture and qPCR.
A good correlation (> 85%) between qPCR and direct cul-
ture was observed for most populations investigated. The
lowest correlation value, 62%, was observed between the
qPCR assay for Enterobacteriaceae and selective culture for
lactose-fermenting Enterobacteriaceae populations, partially
due to the different trends observed between assays during
Fig. 4 Levels of bacterial populations in vessel 3 of model A, B and C. (a) qPCR results for C. coccoides group in log10 copies/μL, (b) culture results
in log10 cfu/mL for total clostridia, (c) qPCR results for Enterobacteriaceae in log10 copies/μL, (d) culture results in log10 cfu/mL for lactose-
fermenting Enterobacteriaceae. CD, C. difficile; rCDI, recurrent CDI; FMT, faecal microbiota transplantation. Asterisks represent significant variations
by qPCR between time points: *correspond to p < 0.05, **correspond to p < 0.005, and ***correspond to p < 0.0005
Table 2 Pearson correlation coefficient analysis between bacterial enumeration and qPCR in the pre FMT period
Bacterial population R value R2 value
Culture assay 16S target by qPCR
Total bacteria (cultured anaerobically) Total bacteria (Eubacteria) 0.93 0.86
Lactose-fermenting Enterobacteriaceae Enterobacteriaceae 0.79 0.62
Enterococcus spp. Enterococcus spp. 0.92 0.85
Bacteroides spp. Bacteroides spp. 0.99 0.98
Bifidobacterium spp. Bifidobacterium spp. 0.86 0.73
Lactobacillus spp. Lactobacillus spp. 0.97 0.94
Clostridium spp. C. coccoides 0.79 0.63
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vancomycin dosing. Escherichia spp., Klebsiella spp., Citro-
bacter spp., and Enterobacter spp. species are among the
genera of the normal intestinal flora of humans that have
the capacity to process lactose [26]. However, some genera
within the Enterobacteriaceae family are non-lactose fer-
menters and may require other media for its selective cul-
ture [26, 27]. Among these, Salmonella spp., Shigella spp.,
Serratia spp., and Proteus spp. species can be part of the
human gastrointestinal microbiota, and their presence was
confirmed in these gut models by MALDI-TOF iden-
tification of selected colonies in non-selective nutrient
agar. As the qPCR reaction targets the 16S region of
the overall Enterobacteriaceae gut populations without
distinguish the lactose fermenting species, this pos-
sibly explains the lower correlation observed in this
case between qPCR and bacterial culture.
Prevotella spp., C. coccoides and C. leptum populations
were investigated due to their importance for a healthy
microbiome [16, 19, 20, 24]. We found that direct
enumeration of Clostridium spp. correlated with the qPCR
results for C. coccoides based on the specificity of this pri-
mer pair for clostridia species commonly isolated from
gut model samples; however, not all Clostridium species
were amplified. Correlation between culture of Clostrid-
ium spp. and the qPCR assay for C. coccoides mostly dif-
fered during clindamycin dosing period, when culture
showed a high decline in clostridia counts that was less
noticeable by qPCR. Within the Clostridium genus, C. coc-
coides (Clostridium cluster XIVa) and C. leptum (Clostrid-
ium cluster IV) are two highly predominant groups of the
human gastrointestinal tract [16, 17, 19, 24]. Each of these
groups is complex, with C. cocoides being closer in com-
position to the Lachnospiraceae family and C. leptum to
the Ruminococcaceae family. C. coccoides includes Butyri-
vibrio, Clostridium, Coprococcus, Dorea, Eubacterium,
Lachnospira, Roseburia, and Ruminococcus species, and C.
leptum includes Clostridium, Ruminococcus, Eubacterium
and Faecalibacterium prausnitzii species [17, 18, 24, 28].
Since several bacterial populations are represented in the
C. coccoides group, it is likely that some species within the
group were less disturbed by clindamycin instillation,
which was reflected in the qPCR assay results.
In this study, C. difficile was investigated using two
qPCR assays, one for the species 16S region and other
for the housekeeping gene gluD. Results consistently
showed C. difficile levels ~ 1 log10 copies/μL higher in
the 16S gene assay compared to the gluD assay. Concen-
trations of C. difficile genomic DNA ranging from 12.5
ng to 0.024 ng were tested with both primer sets, show-
ing results ~ 1.5 log10 copies/μL higher in the 16S assay
compared to gluD. As C. difficile genome has 11 copies
of the 16S rRNA operon and 1 copy of the gluD gene
[29] this could possibly explain the apparent higher sen-
sitivity of the 16S qPCR assay.
Overall, both quantitative analyses of gastrointestinal bac-
terial populations showed an earlier reconstitution of the
gut microbiota in the models that received an FMT. Al-
though both assays provide absolute quantification data,
they have different limits of detection. As example, Bifido-
bacterium spp. was periodically undetectable by direct cul-
ture, whereas all commensal populations remained
detected by qPCR throughout the experiment. Although
the assays showed a good correlation, an improvement is
likely to be observed if the limits of detection of both meth-
odologies are taken into consideration. qPCR allowed us to
monitor bacterial groups that would otherwise not be pos-
sible to investigate and offered a shorter turnaround time
(less than 24 h) for results compared with culture. In
addition to its high sensitivity, qPCR also allowed analysis
of higher number of technical replicates adding the possi-
bility of statistical analysis. However, by detecting DNA, we
are unable to distinguish between viable and non-viable
cells. Despite having a slower turnaround time, particularly
for anaerobic populations that require 48 h incubation, the
culture results reflect cell viability and coupled with
MALDI-TOF identification, provided additional quantita-
tive information on the most abundant bacterial species in
the gut model at a given time. This allows for a better un-
derstanding of any specific pathways that may be active and
their potential relevance in disease. Studies involving moni-
toring of multiple populations by culture assay can be chal-
lenging, however, for the phylogenetically inconsistent
clostridia genus [28], the use of a single selective medium
in this study allowed the monitoring of high abundant Clos-
tridium species. Additionally, with bacterial culture, we
were able to monitor C. difficile at different stages of the
bacteria life cycle, by differentiate spores and vegetative cells
which was not possible using qPCR.
Conclusions
Overall, the commensal bacterial populations monitored in
this study showed a quicker recovery in the models that re-
ceived an FMT, compared to treatment with vancomycin
only. Alongside this recovery, the models that received an
FMT did not show recurrent infection, whereas model A
showed C. difficile proliferation and toxin production, con-
sistent with rCDI. These results show the potential of re-
placement therapies in the reconstitution of the normal
human microbiota. Furthermore, the qPCR assays corre-
lated well with the results of bacterial enumeration by cul-
ture, with both methods showing antibiotic-mediated
depletion of the gut microbiota populations, followed by re-
constitution of gastrointestinal populations within four
weeks. The molecular assays can potentially provide infor-
mation on gut bacterial variations in real-time, reducing the
standard requirements for bacterial culture, and allowing
the monitoring of bacterial groups that would otherwise not
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be possible. However, in some cases it may not be possible
to monitor an individual genus without selective culture.
Methods
Chemostat model assembly and experimental design
Three triple-stage chemostat models, assembled as previ-
ously described [9, 14] were run simultaneously. Briefly,
each model consists of three glass vessels displayed in a
weir cascade and kept at 37 °C by a water jacket. This sys-
tem simulates the nutrient availability and pH conditions
of the proximal, medial and distal colon in vessel 1, 2 and
3, respectively. The models are continuously fed with a
complex nutritive medium (Table 3), at the pre-
established dilution rate of 15mL/h and an anaerobic en-
vironment was maintained by sparging the system with ni-
trogen. All models were inoculated with a slurry of pooled
human faeces [10% w/v in pre-reduced phosphate buff-
ered saline (PBS)] from 22 healthy volunteers, > 60 years
of age, and with no history of antibiotic therapy in the pre-
vious 6months. In each model, bacterial populations were
allowed to equilibrate for 4 weeks, followed by addition of
two doses of 107 cfu/mL C. difficile spores, a week apart.
C. difficile spores of the PCR ribotype 027 strain 210 were
prepared as described before [30], and added to the model.
CDI was induced following clindamycin instillation (33.9
mg/L, four times daily for 7 days) (Fig. 1). C. difficile ger-
mination, growth and toxin production were monitored
and at peak toxin production, all models were dosed with
vancomycin (125mg/L, four times daily for 7 days). Anti-
biotic treatments were based on previously reported faecal
concentrations and prescribing recommendations for
these drugs [12, 31]. Three days post vancomycin, model
A was left without further intervention, whereas models B
and C were treated with an FMT preparation. Up to the
end of vancomycin treatment, all models followed the
same experimental design, representing replicates for sim-
ulated CDI and treatment, as previously described [11–
13]. Afterwards, model A proceeded as a representation of
a simulated rCDI case, whereas model B and C proceeded
as replicates of a simulated FMT treatment. The FMT ex-
periment was performed in duplicate to confirm method
reproducibility in the chemostat model. FMT was pre-
pared similar to the initial slurry, by performing a 10-fold
dilution with pre-reduced PBS of a faecal sample donated
by a relative of one of the initial donors, aged 30, without
history of antibiotic use in the previous 6months. The
FMT (50mL) was added to the bottom of vessel 1 of
models’ B and C at a 50mL/h rate using a peristaltic
pump. Microbial populations were monitored for 4 weeks
post instillation in all models.
Table 3 Target populations and agar composition for bacterial ennumeration
Gut model growth medium
Solid components (g/L):
Peptone water (2.0), yeast extract (2.0), NaCl (0.1), K2HPO4 (0.04), KH2PO4 (0.04), MgSO4.7H2O (0.01), CaCl2.2H2O (0.01), NaHCO3 (2.0), haemin (0.005),
cysteine HCl (0.5), bile salts (0.5), glucose (0.4), arabinogalactan (1.0), pectin (2.0), starch (3.0)
Liquid components:
vitamin K1 at 10 mL/L, and Tween 80 at 0.2%
Medium is sterilised at 121 °C for 30 min and cooled to 50 °C. Post-autoclaving glucose (0.4 g/L), and resazurin anaerobic indicator (0.005 g/L) are
added.
Target populations Agar Supplements Incubation (temp, environment)
Total anaerobes and
total Clostridium spp.
Fastidious anaerobe agar 5% horse blood 37 °C, anerobic
Bifidobacterium spp. 42.5 g/L Columbia agar,
and 5 g/L agar technical
0.5 g/L cysteine HCl, 5 g/L glucose 37 °C, anerobic
Bacteroides spp. Bacteroides bile aesculin agar 5 mg/L haemin, 10 μL/L vitamin K, 7.5 mg/L
vancomycin, 1 mg/L penicillin, 75 mg/L
kanamycin and 10mg/L colistin
37 °C, anerobic
Lactobacillus spp. 52.2 g/L MRS broth and
20 g/L agar technical
0.5 g/L cysteine hydrocloride, 20 mg/L
vancomycin
37 °C, anerobic
Total facultative anaerobes Nutrient agar N/A 37 °C, aerobic
Lactose fermenting
Enterobacteriaceae
MaConkey’s agar N/A 37 °C, aerobic
Enterococcus spp. Kanamycin aesculin azide agar 10 mg/L nalidixic acid, 10 mg/L aztreonam,
and 20mg/L kanamycin
37 °C, aerobic
Total spores (following
alcohol shock for 1 h)
Fastidious anaerobe agar 5% horse blood 37 °C, anerobic
C. difficile total viable cells Braziers CCEY agar D-cycloserine (250 mg/L) cefoxitin (8 mg/L),
5 mg/L lysozyme, and 20mL/L lysed horse
blood
37 °C, anerobic
C. difficile spores Braziers CCEY agar 5 mg/L lysozyme, and 2% lysed horse blood 37 °C, anerobic
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Bacterial culture and cytotoxin assay
Models were sampled for culture profiling of key intestinal
microbiota populations using selective and non-selective
agars described in Table 3. Populations of total bacteria,
Clostridium spp. lactose-fermenting Enterobacteriaceae,
Enterococcus spp., Bacteroides spp., Bifidobacterium spp.,
Lactobacillus spp., C. difficile total viable cells and C. diffi-
cile spores were monitored at the time points illustrated in
Fig. 1. All bacterial populations and C. difficile spores were
cultured as previously described [9]. Briefly, C. difficile
spores were isolated by treating 0.5mL of gut model fluid
with 0.5mL of 96% ethanol. The samples were incubated
at room temperature for 1 h, serially diluted to 10− 3 in
peptone water, and 20 μL of each sample dilution was
plated in triplicate onto supplemented Braziers CCEY agar
(Table 3). Plates were incubated anaerobically for 48 h and
distinctive colonies were enumerated. Identification of
bacterial isolates were confirmed by Matrix-Assisted Laser
Desorption Ionization-Time of Flight (MALDI-TOF).
Vessel 3 was particularly investigated due to its high
microbial content [32] and because it represents the
area of the colon more physiologically relevant for
CDI [33]. The limit of detection for culture assay was
~ 1.22 log10 cfu/mL.
The C. difficile toxin levels were measured by cell
cytotoxicity assay, as previously described [9]. Briefly,
model fluid was centrifuged, filtered, and serially diluted
on a 10-fold series. Each dilution was inoculated onto a
confluent monolayer of Vero cells and incubated for 48
h at 37 °C at 5% CO2. Samples were considered positive
for C. difficile toxin when > 70% cell rounding was ob-
served. Results are expressed as RUs, as follows: positive
result on a 1:10 dilution = 1 RU, 1:100 = 2 RU, etc.
DNA extraction of gut model samples
For molecular analysis, samples were taken from vessel 3 of
each model as outlined in Fig. 1. For each time point, DNA
extraction was performed in triplicate using the FastDNA
Spin kit for Soil (Mpbio) following manufacturer’ instruc-
tions except that sample homogenisation was performed
using Precellys 24 (Bertin Instruments) at 6500 rpm for 40
s. DNA concentration was measured using a Nanodrop
2000c and each sample was normalised to 5 ng/μL.
Preparation of control curves using plasmid standard DNA
For the analysis of Enterococcus spp., Bifidobacterium
spp., Lactobacillus spp., and C. difficile, plasmids contain-
ing 16S gene inserts specific for these populations were
Table 4 Sequence of primers used for each bacterial group
Target Primer Sequence (5′-3′) Product size (bp) Annealing (time, temp) Reference
Bacteroides spp. Bac303F GAAGGTCCCCCACATTG 419 45 s, 54 °C [34]
Bac708R CAATCGGAGTTCTTCGTG
Enterobacteriaceae Eco1457F CATTGACGTTACCCGCAGAAGAAGC 190 45 s, 60 °C [21]
Eco1652 CTCTACGAGACTCAAGCTTGC
C. leptum group Sg-clept-F GCACAAGCAGTGGAGT 241 45 s, 54 °C [19]
Sg-clept-R CTTCCTCCGTTTGTCAA
C. coccoides group Eub338F ACTCCTACGGGAGGCAGC 139 30s, 56 °C [20]
Erec482R GCTTCTTAGTCANGTACCG
Prevotella spp. CFB286F GTAGGGGTTCTGAGAGGA 446 30s, 56 °C [20]
CFB719R AGCTGCCTTCGCAATCGG
Eubacteria 8F AGTTTGATCCTGGCTCAG 417 45 s, 54 °C [35]
515R GNATTACCGCGGCNGCTG
Probe 338P FAM GCTGCCTCCCGTAGGAGT BHQ1
Bifidobacterium spp. Bif551F CGCGTCNGGTGTGAAAG 244 20s, 55 °C [36]
Bif794R CCCCACATCCAGCATCCA
Lactobacillus spp. Lacto-F GAGGCAGCAGTAGGGAATCTTC 126 45 s, 60 °C [36]
Lacto-R GGCCAGTTACTACCTCTATCCTTCTTC
Enterococcus spp. Enter-F CCCTTATTGTTAGTTGCCATCATT 144 20s, 56 °C [22]
Enter-R ACTCGTTGTACTTCCCATTGT
C. difficile (16S gene) Cdiff-F CAAGTTGAGCGATTTACTTCGGTAA 177 20s, 59 °C [37]
Cdiff-R CTAATCAGACGCGGGTCCAT
C. difficile (GluD gene) GluD-F ATGCAGTAGGGCCAACAAAA 135 20s, 55 °C [38]
GluD-R TTCCACCTTTACCTCCACCA
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prepared as described before [23]. Group-specific PCR re-
actions were performed on appropriate bacterial strains
using the primers described in Table 4. The products were
cloned using the TOPO TA cloning kit (Thermo Fisher
Scientific) and inserts were verified by Sanger sequencing
capillary electrophoresis (Applied Biosystems). Bacterial
group specificity of the insert in transformed colonies was
confirmed by blastn search and plasmid DNA was isolated
using QIAprep spin miniprep kit (Qiagen). Plasmids con-
taining 16S gene inserts for total bacteria, Enterobacteria-
ceae, Bacteroides spp., Prevotella spp., Clostridium
coccoides and Clostridium leptum were provided by Dr.
Cheleste M. Thorpe (Tufts Medical Center, USA) [23].
Plasmids were re-suspended, propagation was performed
using TOP10 chemically competent Escherichia coli cells
(Thermo Fisher Scientific) according to manufacturers’ in-
structions, and plasmid DNA was obtained as above. The
molecular weight of each plasmid containing 16S gene in-
serts was determined using a web calculator (http://www.
encorbio.com/protocols/Nuc-MW.htm). Purified plasmid
concentrations were determined using Qubit 2.0
Fluorometer and 10-fold dilution series ranging from 5 ×
109 copies/μL to 500 copies/μL were prepared.
qPCR assays and data analysis
The DNA levels of each bacterial genus/species were
assessed using primers previously validated for qPCR
(Table 4). Reactions containing final concentration of
SYBR Green 1x Master Mix (Qiagen), 0.3 μM primers
and 12.5 ng of DNA template were prepared to a final
volume of 10 μL. A FAM-tagged probe at 0.25 μM was
added to the Eubacteria reaction mix [23]. Reactions
were analysed in a 7500 Real-Time PCR System
(Thermo Fisher). DNA extraction replicates were run in
duplicate for all bacterial populations investigated. Plas-
mid DNA standard curves were included on each qPCR
plate in triplicate and used to convert threshold cycle
values to copies per μL of template. The same concen-
tration (12.5 ng) of DNA template and plasmid DNA
standard was used in each reaction. Standard curve R
square values ranged from 0.990 ± 0.009. Limit of detec-
tion was established at 500 copies. The change in bacter-
ial levels were calculated based on logarithms of 16S
rRNA gene copy numbers to achieve normal distribu-
tion. GraphPad Prism was used for analysis of log trans-
formed data. Statistical significance between time-points
was assessed using a two-sided Wilcoxon Signed Rank
test with a 95% confidence interval. P ≤ 0.05 was consid-
ered statistically significant.
Study of Clostridium species
C. difficile was investigated using two qPCR assays, one
targeting the housekeeping gene gluD, and another tar-
geting the 16S gene. Specificity of the primer sets was
investigated by standard PCR. DNA template of Clos-
tridium species isolated from gut model samples and
identified by MALDI-TOF were amplified using the
primers for C. coccoides group, C. leptum group and C.
difficile 16S gene (Table 4) to determine primer specifi-
city (Table 1).
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s12866-019-1669-2.
Additional file 1: Figure S1. Mean gut microbiota populations of C.
difficile based on the housekeeping gene gluD in vessel 3 of model A, B
and C at the different stages of the experiment. Bar graphs represent the
levels in log10 copies/μL measured by qPCR. CD, C. difficile; rCDI, recurrent
CDI; FMT, faecal microbiota transplantation. Asterisks represent significant
variations by qPCR between time points: *correspond to p < 0.05, and
***correspond to p < 0.0005. (TIF 619 Kb)
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